Edition:
United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.78USD
12 Dec 2017
Change (% chg)

$-0.05 (-2.73%)
Prev Close
$1.83
Open
$1.85
Day's High
$1.85
Day's Low
$1.77
Volume
10,448
Avg. Vol
58,008
52-wk High
$3.69
52-wk Low
$1.66

Chart for

About

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $23.07
Shares Outstanding(Mil.): 12.61
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-‍Stonepine Capital Management reports 6.6 pct passive stake in Vical

* ‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​ Source text: (http://bit.ly/2z2Y7Nh) Further company coverage:

Nov 15 2017

BRIEF-Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock

* Vical Incorporated announces pricing of $25 million underwritten public offering of common stock

Nov 08 2017

BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION

* VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION

Oct 24 2017

BRIEF-Vical reports Q3 loss per share $0.27

* Vical reports third quarter 2017 financial and operational results

Oct 23 2017

BRIEF-Vical Inc files for common stock offering of up to $23.0 mln

* Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​ Source: (http://bit.ly/2gnoSUA) Further company coverage:

Oct 16 2017

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

Oct 10 2017

BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA

* Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial

Oct 02 2017

BRIEF-Vical Inc Q2 loss per share $0.30

* Vical reports second quarter 2017 financial and operational results

Aug 08 2017

Competitors

Earnings vs. Estimates